Rare cancer, cancer of unknown primary, and rare histological subtypes of common cancers
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 0 years or older at registration. 2. Patients with histological diagnosis of rare cancer, cancer of unknown primary, or rare histological subtypes of common cancers. 3. Patients with incurable progressive (metastatic and/or unresectable) lesions (number of prior regimens will not be limited). 4. Patients who had already received next-generation sequencing (NGS) or molecular diagnostic testing (e.g., immunohistochemical staining, FISH), patients with these tests requested, or patients who have provided oral or written consent for these tests (whether conducted by either own site or an external laboratory). 5. Patients who provided a written consent to participate in the study (for patients less than 20 years of age, their legally acceptable representative must give consent). However, those who are physically unable to give a signature can have it done by someone appointed by the patient.
Exclusion criteria
Exclusion criteria: 1. Patients with complications of psychiatric disorders/symptoms that interfere daily life are considered to hamper their participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Overall incidence of genetic abnormality 2) Incidence of individual genetic abnormalities 3) Biomarker-positive rate 4) Number of somatic mutations and distribution of mutation rate within exons 5) Response rate 6) Disease control rate 7) Overall survival 8) Progression-free survival | — |
Countries
Japan
Contacts
Public ContactMasahiko Ichimura
National Cancer Center Hospital Clinical Trial Management Section, Research Management Division, Clinical Research Support Office
Outcome results
None listed